DOI QR코드

DOI QR Code

Pin1 Promoter rs2233678 and rs2233679 Polymorphisms in Cancer: A Meta-analysis

  • Zhu, Yan-Mei (Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, the Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department) ;
  • Liu, Jing-Wei (Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, the Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department) ;
  • Xu, Qian (Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, the Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department) ;
  • Yuan, Yuan (Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, the Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department)
  • Published : 2013.10.30

Abstract

PIN1 is one member of the parvulin PPIase family. By controlling Pro-directed phosphorylation, PIN1 plays an important role in cell transformation and oncogenesis. There are many polymorphisms in the PIN1 gene, including rs2233678 and rs2233679 affecting the PIN1 promoter. Recently, a number of case-control studies were conducted to investigate the association between PIN1 gene rs2233678 and rs2233679 polymorphism and cancer risk. However, published data are still conflicting. In this paper, we summarized data for 5,427 cancer cases and 5,469 controls from 9 studies and attempted to assess the susceptibility of PIN1 gene polymorphism to cancers by a synthetic meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the relationship. All analyses were performed using Stata software. Our results suggested that rs2233678 represented a protective factor in overall analysis (CC vs GG: OR= 0.697, 95%CI: 0.498-0.976; CG vs GG: OR=0.701, 95%CI: 0.572-0.858; Dominant model: OR= 0.707, 95%CI: 0.590-0.847; C allele vs G allele: OR=0.734, 95%CI: 0.623-0.867) and especially for squamous cell carcinoma of the head and neck, lung cancer and breast cancer in Asians and Caucasians. The rs2233679 polymorphism was significantly associated with decreased cancer risk in overall analysis (CT vs CC: OR=0.893, 95%CI=0.812-0.981; Dominant model: OR=0.893, 95%CI=0.816-0.976; T allele vs C allele; OR=0.947, 95%CI=0.896-1.000) and especially in Asians. In conclusion, our meta-analysis suggested that -842G>C (rs2233678) and -667C>T (rs2233679) may contribute to genetic susceptibility for cancer risks. Further prospective research with larger numbers of worldwide participants is warranted to draw comprehensive and firm conclusions.

Keywords

PIN1;single nucleotide polymorphism;cancer;susceptibility;meta-analysis

References

  1. Carpenter RW, Tomko RL, Trull TJ, Boomsma DI. (2013). Gene-environment studies and borderline personality disorder: a review. Curr Psychiatry Rep, 15, 336. https://doi.org/10.1007/s11920-012-0336-1
  2. Ayala G, Wang D, Wulf G, et al (2003). The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res, 63, 6244-51.
  3. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  4. Cao WP, Tang HL, Lin P (2012). Association between polymorphisms in prolyl isomerase Pin1 and risk for laryngeal squamous cell carcinoma. Jiangsu Med, 38, 1067-670.
  5. Chung CC, Chanock SJ (2011). Current status of genome-wide association studies in cancer. Hum Genet, 130, 59-78. https://doi.org/10.1007/s00439-011-1030-9
  6. DeYoung CG, Clark R (2012). The gene in its natural habitat: the importance of gene-trait interactions. Dev Psychopathol, 24, 1307-18. https://doi.org/10.1017/S0954579412000727
  7. Dick, DM (2011). Gene-environment interaction in psychological traits and disorders. Annu Rev Clin Psychol, 7, 383-409. https://doi.org/10.1146/annurev-clinpsy-032210-104518
  8. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. Euhus DM, Robinson L (2013). Genetic predisposition syndromes and their management. Surg Clin North Am, 93, 341-62. https://doi.org/10.1016/j.suc.2013.01.005
  10. Fukuchi M, Fukai Y, Kimura H, et al (2006). Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol, 29, 329-34.
  11. Gao LB, Pan XM, Sun H, et al (2010). The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis. J Exp Clin Cancer Res, 29, 117. https://doi.org/10.1186/1756-9966-29-117
  12. Liou YC, Zhou XZ, Lu KP (2011). Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci, 36, 501-14. https://doi.org/10.1016/j.tibs.2011.07.001
  13. Han CH, Lu J, Wei Q, et al (2010). The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat, 122, 243-9. https://doi.org/10.1007/s10549-009-0682-9
  14. He J, Zhou F, Shao K, et al (2007). Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer, 56, 51-8. https://doi.org/10.1016/j.lungcan.2006.11.024
  15. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  16. Lu J, Hu Z, Wei S, et al (2009). A novel functional variant (-842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis, 30, 1717-21. https://doi.org/10.1093/carcin/bgp171
  17. Lu J, Yang L, Zhao H, et al (2011). The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum Mutat, 32, 1299-308. https://doi.org/10.1002/humu.21574
  18. Lu KP, Zhou XZ (2007). The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol, 8, 904-16. https://doi.org/10.1038/nrm2261
  19. Lu Y, Huang GL, Pu XX, et al (2013). Association between PIN1 promoter polymorphisms and risk of nasopharyngeal carcinoma. Mol Biol Rep, 40, 3777-82. https://doi.org/10.1007/s11033-012-2454-6
  20. Miyashita H, Mori S, Motegi K, et al (2003). Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. Oncol Rep, 10, 455-61.
  21. Ramsberg J, Asseburg C, Henriksson M (2012). Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One, 7, e42003. https://doi.org/10.1371/journal.pone.0042003
  22. Molina JD, Lopez-Munoz F, Stein DJ, et al (2009). Borderline personality disorder: a review and reformulation from evolutionary theory. Med Hypotheses, 73, 382-6. https://doi.org/10.1016/j.mehy.2009.03.024
  23. Naidu R, Har YC, Taib NA (2011). Analysis of peptidyl-propyl-cis/trans isomerase 1 (PIN1) gene -842(G > C) and -667(T> C) polymorphic variants in relation to breast cancer risk and clinico-pathological parameters. Scand J Clin Lab Invest, 71, 500-6. https://doi.org/10.3109/00365513.2011.590223
  24. Perez-Losada J, Castellanos-Martin A, Mao JH (2011). Cancer evolution and individual susceptibility. Integr Biol (Camb), 3, 316-28. https://doi.org/10.1039/c0ib00094a
  25. Segat L, Milanese M, Crovella S (2007). Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology, 132, 2618-9; author reply 9-20. https://doi.org/10.1053/j.gastro.2007.04.037
  26. Theuerkorn M, Fischer G, Schiene-Fischer C (2011). Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol, 11, 281-7. https://doi.org/10.1016/j.coph.2011.03.007
  27. Xue H, Lin B, Ni P, et al (2010). Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol, 25, 1604-17. https://doi.org/10.1111/j.1440-1746.2010.06428.x
  28. You Y, Deng J, Zheng J, et al (2013). Functional polymorphisms in PIN1 promoter and esophageal carcinoma susceptibility in Chinese population. Mol Biol Rep, 40, 829-38. https://doi.org/10.1007/s11033-012-2122-x
  29. Zhao H (2009). Association between polymorphisms in prolyl isomerase Pin1 promoter and risk for lung cancer. . Guangzhou Medical University: [D] Guangzhou.

Cited by

  1. Four Polymorphisms in the Cytochrome P450 1A2 (CYP1A2) Gene and Lung Cancer Risk: a Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5673